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The biological fates of the key initiator of Alzheimer’s disease (AD), the amyloid precursor
protein (APP), and a family of lipoprotein receptors, the low-density lipoprotein (LDL)
receptor-related proteins (LRPs) and their molecular roles in the neurodegenerative
disease process are inseparably interwoven. Not only does APP bind tightly to the
extracellular domains (ECDs) of several members of the LRP group, their intracellular
portions are also connected through scaffolds like the one established by FE65 proteins
and through interactions with adaptor proteins such as X11/Mint and Dab1. Moreover,
the ECDs of APP and LRPs share common ligands, most notably Reelin, a regulator
of neuronal migration during embryonic development and modulator of synaptic
transmission in the adult brain, and Agrin, another signaling protein which is essential
for the formation and maintenance of the neuromuscular junction (NMJ) and which likely
also has critical, though at this time less well defined, roles for the regulation of central
synapses. Furthermore, the major independent risk factors for AD, Apolipoprotein (Apo)
E and ApoJ/Clusterin, are lipoprotein ligands for LRPs. Receptors and ligands mutually
influence their intracellular trafficking and thereby the functions and abilities of neurons
and the blood-brain-barrier to turn over and remove the pathological product of APP,
the amyloid-β peptide. This article will review and summarize the molecular mechanisms
that are shared by APP and LRPs and discuss their relative contributions to AD.
Keywords: LRP, APOE, LDL receptor gene family, neuromuscular junction, synapse, glutamate receptors,
trafficking, amyloid beta
LIPOPROTEIN RECEPTORS
Structure and General Physiological Properties
Besides the important role in lipid metabolism, members of the low-density lipoprotein
(LDL) receptor family take part in a broad range of pre- and post-developmental functions
in brain and play key roles in the pathogenesis of Alzheimer’s disease (AD). Much like the
amyloid precursor protein (APP), members of the LDL receptor family are type-I membrane
receptors with single-pass transmembrane (TM) domains that can be endocytosed, proteolytically
processed and participate in a variety of protein interactions both inside and outside of the cell,
including direct interactions with APP (May et al., 2005; Dieckmann et al., 2010). Lipoprotein
receptors are involved in various mechanisms of APP-processing and Aβ-clearance in several
cell types including neurons, astrocytes, endothelial cells of the blood brain barrier (BBB), and
ependymal cells of the blood cerebrospinal fluid (CSF) barrier (BCSFB; reviewed by Hoe and
Rebeck, 2008; Marzolo and Bu, 2009; Wagner and Pietrzik, 2012; Lane-Donovan et al., 2014).
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In the peripheral and central nervous system, lipoprotein
receptors and APP interact to control developmental processes
and synaptic function. These lipoprotein receptors are highly
conserved—at least as far back in evolution asC. elegans (Yochem
and Greenwald, 1993)—and are related by both structure and
function (Krieger and Herz, 1994; Figure 1). The seven core
members of this receptor family are the LDL receptor (Ldlr),
Apolipoprotein E (ApoE) receptor 2 (Apoer2/Lrp8), very-LDL
receptor (Vldlr), LDL receptor-related protein 1 (Lrp1), Lrp1b,
Lrp2/Megalin and multiple epidermal growth factor (EGF)
repeat containing protein 7 (Megf7/Lrp4; Dieckmann et al.,
2010). Structurally, the extracellular domain (ECD) of each
of the core LDL receptor family members is composed of a
combination of two types of conserved domains: (1) ligand
binding-type repeat domains (LBDs); and (2) EGF-precursor
homology domains. The amino-terminal LBD domain confers
ligand specificity, consisting of cysteine-rich complement-type
ligand binding-type repeats (LBRs, sometimes called type
A repeats). The EGF-precursor domains participate in the
pH-dependent release of bound ligands after endocytosis and
contain a mixture of EGF receptor-like repeats (EGF-repeats)
and YWTD (Tyr-Trp-Thr-Asp) β-propeller repeats (Beglova
and Blacklow, 2005; Andersen et al., 2013; reviewed in Li
et al., 2001). The intracellular domain is less conserved between
the family members, but each of the core members contain
at least one NPxY (Asn-Pro-X-Tyr) motif that functions in
protein interaction/signal transduction (Trommsdorff et al.,
1998; Howell et al., 1999; Gotthardt et al., 2000) and endocytosis
(Chen et al., 1990).
The smaller receptors within the LDL receptor family, Ldlr,
Vldlr and Apoer2, contain only one EGF-precursor domain and
have a juxtamembraneous domain rich in serine and threonine
residues, which serve as sites for O-linked glycosylation (Kingsley
et al., 1986; Sakai et al., 1994; Christie et al., 1996; Kim et al.,
1996). This O-linked sugar (OLS) domain is alternatively spliced
in both Apoer2 and Vldlr (Sakai et al., 1994; Kim et al., 1997;
Clatworthy et al., 1999), and inclusion of the OLS-domain
hinders the proteolytic processing of the receptors (Magrané
et al., 1999; May et al., 2003; Wasser et al., 2014). However, for
Apoer2 it was shown that exclusion of the OLS-domain produces
‘‘cleavage-resistant’’ Apoer2 splice variants, as the OLS-domain
is likely the site of the initial extracellular cleavage that precedes
further processing by γ-secretase (Wasser et al., 2014).
Additional somewhat distant members are Lrp5 and Lrp6 as
well as the Sortilin-related receptor with LDLR class A
repeats (SorLA; Figure 1). Lrp5 and Lrp6 (called arrow in
D. melanogaster) encode four EGF-precursor domains but
lack N-terminal LBDs and intracellular NPxY-motifs (Brown
et al., 1998; Nakagawa et al., 1998; Wehrli et al., 2000).
SorLA (SorL1/LR11/Lrp11), with multiple LBDs and one
EGF-precursor domain, is a hybrid-LDL receptor family member
in that it has an additional Vps10p-sorting domain and
Fibronectin repeats (Jacobsen et al., 1996). In addition, SorLA
has one NPxY-related retromer binding motif (FANSHY; Phe-
Ala-Asn-Ser-His-Tyr; Fjorback et al., 2012). Containing three to
five LBRs and no other typical LDL receptor domains, the most
distant relatives are Lrad3 (Ranganathan et al., 2011) as well as
Lrp3 (Ishii et al., 1998), Lrp10 (murine Lrp9; Sugiyama et al.,
2000) and Lrp12 (ST7/Mg13; Battle et al., 2003), which have two
additional CUB domains.
Genetics
Despite the high degree of homology between the receptors and
the overlapping expression pattern and function, the majority
of these receptors are indispensable for survival or proper
brain function. In fact, deletion of Lrp1 (Herz et al., 1992),
Lrp1b (Dietrich et al., 2014), Lrp2 (Willnow et al., 1996), Lrp4
(Weatherbee et al., 2006) or Lrp6 (Pinson et al., 2000) in the
mouse lead to embryonic or postnatal death with complete or
high penetrance. While mice lacking Lrp5 (Fujino et al., 2003),
Ldlr (Shimada et al., 1996), Apoer2 or Vldlr (Trommsdorff et al.,
1999), or the distant member SorLA (Andersen et al., 2005)
survive, they all have abnormalities in cholesterol homeostasis
and/or brain development. Of the most distant relatives, gene
silencing of Lrp12 leads to defects in brain lamination (Grote
et al., 2016), yet to date in vivo knockouts or knockdowns of




One percent of all AD cases are early onset (EOAD) generally
manifesting from mutations in APP or APP processing genes
and leading to increased production of the toxic APP cleavage
product, amyloid β (Aβ). The other 99% of cases are late-onset
AD (LOAD) with increased Aβ-levels and deposition that are
apparently independent from EOAD-likemutations in APP/APP
processing genes. Instead, the leading cause in LOAD appears to
be an imbalance between Aβ production and clearance from the
brain (Weller et al., 2008; Mawuenyega et al., 2010). Thus, it is
important to understand the various mechanisms by which LDL
receptor family members and their ligands clear Aβ.
Aside from age, the most important risk modifier for
developing LOAD is ApoE (Corder et al., 1993). ApoE is a major
cholesterol transporter in the brain and in the circulation. In
humans there are three ApoE alleles: ε2, ε3, and ε4 (ApoE2,
3 and 4, respectively). ApoE3 is the most abundant allele
and understood as the neutral isoform with regards to AD-
physiology, the least abundant isoform ApoE2 appears to be
protective against AD (Corder et al., 1994; Conejero-Goldberg
et al., 2014). Importantly, the ε4 allele of ApoE (ApoE4)
dramatically reduces the age of AD onset and is carried by>50%
of those afflicted with the disease (Corder et al., 1993), despite
an allele frequency of only ∼15% in the general population
(Utermann et al., 1980). Therefore ApoE4 is the most prevalent,
biomedically important risk allele for LOAD.
The brain is the most cholesterol-rich organ, containing
approximately 25%–30% of the body’s total cholesterol (Dietschy
and Turley, 2001), and high serum cholesterol levels correlate
with cognitive impairment and AD (Zambón et al., 2010;
Di Paolo and Kim, 2011). Interestingly, evidence from in vivo
studies suggests that altered serum cholesterol levels affect the
processing of APP as well as the neurotoxicity and clearance
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FIGURE 1 | The low-density lipoprotein (LDL) receptor family. Schematic diagram depicting the domain structure of the LDL receptor family members classified
as (from left to right): core, distant and the far side. The seven core members (left) are LDL receptor (Ldlr), very-LDL receptor (Vldlr), Apolipoprotein E (ApoE) receptor
2 (Apoer2/Lrp8), LDL receptor related protein (Lrp)-4 (Lrp4), Lrp1, Lrp1b and Lrp2. These members are classified as core members by the presence of at least one
NPxY-motif (asterisk) and a combination of two classical LDL receptor domains: (1) N-terminal ligand binding domain composed of cysteine-rich ligand binding-type
repeats (blue); and (2) epidermal growth factor (EGF)-precursor homology domain (orange) composed of EGF-repeats and YWTD/β-propeller domain. Ldlr, Vldlr and
Apoer2 express an additional extracellular O-linked sugar (OLS) domain adjacent to the transmembrane (TM) segment. The more distant members (middle) are the
NPxY-lacking Lrp5/Lrp6 and hybrid SorLA with additional Fibronectin repeats (pink) and importantly the VPS10p-sorting motif (green). Four very distant “far side”
proteins (right, Lrp3, Lrp10, Lrp12, and Lrad3) only encode ligand binding-type repeats. Lrp3, Lrp10 and Lrp12 also contain atypical CUB-domain (binds
Complement, Uegf and Bmp1). In addition to the OLS domains of Apoer2 and Vldlr, alternative splicing of Apoer2 produces splice variants lacking N-terminal ligand
binding type repeats (repeats 4–6; Brandes et al., 2001; gray).
of Aβ (Reed et al., 2014). Despite this, the role of cholesterol
metabolism in the pathogenesis of AD is not well understood.
The cholesterol metabolism link to AD pathogenesis is
further supported by additional genome-wide association studies
that implicate other apolipoproteins and their receptors as
AD risk factors. In addition to ApoE, a variety of SNPs
in ApoJ/Clusterin from several populations are associated
with LOAD (Harold et al., 2009; Bagyinszky et al., 2014).
Other apolipoprotein polymorphisms associated with AD have
been reported in ApoA-I (Shibata et al., 2013), ApoA-IV
(Császár et al., 1997), ApoC-I (Ki et al., 2002; Zhou et al.,
2014; Shang et al., 2015), ApoC-II (Schellenberg et al., 1992),
ApoC-III (Sun et al., 2005) and ApoD (Shibata et al., 2013).
Among the LDL receptor family members, mutations in
SorLA (Meng et al., 2007; Bagyinszky et al., 2014) appear
to impart the most dramatic risk for developing AD. Aside
from SorLA, Lrp1 (Kang et al., 1997), Lrp1b (Shang et al.,
2015), Lrp2 (Wang et al., 2011), Lrp4 (Vargas et al., 2010),
Lrp6 (De Ferrari et al., 2007) and Apoer2 (Ma et al.,
2002) have been associated with AD risk. Furthermore, a
non-LDL receptor family member, Trem2 (triggering receptor
expressed on myeloid cells 2), is an alternative receptor
for apolipoproteins, including ApoE and ApoJ/Clusterin, and
has recently been identified as high risk factor for LOAD
(Jin et al., 2015). In sum, cholesterol metabolism and the
homeostasis/signaling of lipoprotein receptors and their ligands
appear to be inextricably linked to the pathogenesis of
LOAD.
With diverse functions including gathering nutrients and
clearing toxic, useless debris from the extracellular space, as
well as mediating intracellular trafficking/signaling and even
transcription, the indispensable nature ofmany of the lipoprotein
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receptors is not surprising. Most of these receptors play some
part in APP processing or clearance of Aβ, affecting the
balance between Aβ-production and clearance. Understanding
how these lipoprotein receptors and their ligands influence
the homeostasis of Aβ production/clearance individually, as
well as in unison, will prove crucial for not only elucidating
mechanisms of AD pathogenesis, but also the design of potential
therapeutic interventions to counteract the disease. In this
chapter, we will focus on lipoprotein receptors and their role
in AD pathogenesis through regulating APP processing and Aβ
clearance.
Ldlr
Structure and General Physiological
Properties
Ldlr, the founding member of the LDL receptor family, is
ubiquitously expressed throughout the body, where it plays
a key role in regulating cholesterol homeostasis (reviewed
in Go and Mani, 2012). The receptor clusters after binding
cholesterol-rich LDL particles and mediates cholesterol uptake
through clathrin-mediated endocytosis of the lipoprotein-bound
receptor (reviewed in Brown and Goldstein, 1979). Mutations in
the Ldlr gene are responsible for familial hypercholesterolemia
(FH), a disease in which Ldlr function is impaired, leading
to increased plasma cholesterol concentrations and causing
premature cardiovascular disease (Hobbs et al., 1990; Fass et al.,
1997).
Genetics
While impaired Ldlr function in humans leads to elevated
plasma cholesterol and premature cardiovascular disease due
to reduced uptake of cholesterol-rich LDLs (Hobbs et al.,
1990; Fass et al., 1997), the effect in mice is similar yet
less severe (Ishibashi et al., 1993; Osono et al., 1995). In
the CNS, where Ldlr is expressed higher in astrocytes than
in neurons, Ldlr also plays a role in cholesterol homeostasis
in the brain. Ldlr knockout mice display some synaptic and
learning deficiencies (Mulder et al., 2004, 2007; de Oliveira
et al., 2011, 2013, 2014; Moreira et al., 2012). Interestingly,
murine ApoE expression is elevated in the CSF of mice
lacking Ldlr, and this phenotype is even more dramatic
in mice carrying the human ApoE3 and ApoE4 isoforms
of ApoE (Fryer et al., 2005). Ldlr deficiency also leads to
elevated neuroinflammatory responses and oxidative stress
(Thirumangalakudi et al., 2008; Katsouri and Georgopoulos,
2011), which might be further exacerbated by a high cholesterol
diet (Ettcheto et al., 2015).
Biochemistry and Cellular Function
As cholesterol metabolism is linked to AD and regulated by
Ldlr, Ldlr knockout mice have been used as a model organism
to study the interplay between cholesterol and Aβ-deposition
in several studies. While Ldlr has no known direct or indirect
interaction with APP or APP processing, Ldlr binds to Aβ and
mediates its clearance by degradation in astrocytes, but does
not alter APP processing (Kim et al., 2009). Ldlr knockout
mice are more susceptible to Aβ-induced neurotoxicity, when
Aβ is injected into the hippocampus (de Oliveira et al.,
2014). Aβ-deposition is exacerbated with Ldlr-deficiency in AD
mice (Tg2576 and APP/PS1; Cao et al., 2006; Katsouri and
Georgopoulos, 2011) and is attenuated with Ldlr overexpression
on an APP/PS1 background due to enhanced clearance (Kim
et al., 2009). The additional knockout of ApoE does not
affect the Aβ levels in Ldlr-deficient AD mice (APP/PS1;
Katsouri and Georgopoulos, 2011), and this was confirmed
by an in vitro study in astrocytes demonstrating that the
clearance of Aβ is independent of ApoE (Basak et al., 2012).
This suggests that the Ldlr-dependent glia response in Aβ-
clearance is independent of ApoE despite Ldlr being a strong
ApoE receptor (Katsouri and Georgopoulos, 2011; Basak et al.,
2012). Nonetheless, Castellano et al. (2011) showed that Aβ
turnover in the mouse brain in vivo is strongly dependent
upon ApoE isoform, indicating that other mechanisms besides
Ldlr-mediated Aβ removal are responsible for Aβ homeostasis in
the intact brain.
Lrp1
Structure and General Physiological
Properties
The second receptor identified in the LDL receptor family,
Lrp1 (Herz et al., 1988) is one of the largest (∼600 kDa)
and most versatile members as it is known to bind over
100 different ligands (Herz and Strickland, 2001; Gonias and
Campana, 2014). Lrp1 can be processed by the same enzymes
as APP: ADAM10 (Nakajima et al., 2013), BACE1 (von Arnim
et al., 2005) and γ-secretase (May et al., 2002; May and
Herz, 2003; Zurhove et al., 2008). The sequential processing
of Lrp1 first produces a soluble Lrp1-ECD, followed by a
γ-secretase-mediated release of the Lrp1-ICD (May et al., 2002).
The Lrp-ECD is capable of binding Lrp1 ligands (Quinn et al.,
1997), and the Lrp1-ICD can translocate to the nucleus and
regulate gene transcription (Zurhove et al., 2008). Of note,
this Lrp1-ICD-mediated transcriptional regulation might be
relevant to neuroinflammation (Zurhove et al., 2008), which
is emerging as a common factor in many neuropathological
conditions including AD (Heneka et al., 2015; Chen et al., 2016).
Lrp1 also undergoes rapid, constitutive recycling; despite the two
NPxY motifs in the Lrp1 cytoplasmic tail, a YxxL motif in the
intracellular domain of Lrp1 is the dominant and main mediator
of Lrp1 endocytosis—unlike other lipoprotein receptors, where
the NPxYmotifs mediate this process (Li et al., 2000). In addition
to the liver and vasculature, Lrp1 is highly expressed in the
brain (Rebeck et al., 1993) where it plays essential roles in signal
transduction and endocytosis (Herz and Strickland, 2001; May
et al., 2004). During brain development, it modulates radial
glia stem cell proliferation, survival and differentiation (Safina
et al., 2016). Importantly, Lrp1 can regulate the amyloidogenic
processing of APP as well as the clearance of Aβ, which
implicates Lrp1 as a key participant in the pathogenesis of AD
(Kounnas et al., 1995; Ulery et al., 2000; Van Uden et al.,
2000).
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Genetics
Global Lrp1 knockout mice are embryonically lethal (Herz et al.,
1992, 1993). Lrp1 gene polymorphisms have been associated
with a premature risk of cardiovascular disease in patients
with familial hypercholesterolemia/FH (Aledo et al., 2012) and
abnormal inflammatory responses in fibroblasts (Klar et al.,
2015).
Biochemistry and Cellular Function
Lrp1 directly interacts with APP extracellularly and regulates the
localization and processing of APP (Kounnas et al., 1995). In
several cell lines, depletion of the rapidly recycling Lrp1 reduced
Aβ production (Ulery et al., 2000; Pietrzik et al., 2002).
In vivo, overexpression of aminireceptor of Lrp1 (EGF-precursor
domain-II, TM-domain, and ICD-domain) in an AD mouse
model (PDAPP) increased soluble brain Aβ (Zerbinatti et al.,
2004); however, reduced levels of Lrp1 in hippocampal neurons
of another AD mouse model (APP/PS1) had no effect on Aβ
production (Xu et al., 2012).
The extracellular interaction of Lrp1 and APP only occurs
with APP isoforms containing the Kunitz protease inhibitor
(KPI) domain and promotes the internalization of APP (Kounnas
et al., 1995; Billnitzer et al., 2013). The KPI domain is present
in the longer APP isoforms (APP770 and APP751) but not in
the shortest, principally neuronal isoform (APP695), which is
the dominant isoform in the brain (reviewed in Nalivaeva and
Turner, 2013). This Lrp1-APP interaction can be blocked with
the chaperone and Ldlr receptor family member antagonist, RAP
(receptor-associated protein; Kounnas et al., 1995; Kinoshita
et al., 2001). In hippocampal neurons, RAP treatment inhibited
axonal branching due to increased APP on the cell surface that
signals via complex formation with Fe65 and Mena (Ikin et al.,
2007; Billnitzer et al., 2013). In APP knockout neurons, which
have increased axonal branching compared to wildtype, RAP
treatment had an additive Erk2-associated effect on branching
(Billnitzer et al., 2013).
Intracellular interactions with APP and Lrp1 also appear
important in modulating the amyloidogenic processing of APP.
Both Fe65 and Dab1 interact with Lrp1 NPxY motifs and modify
intracellular signal transduction (Trommsdorff et al., 1998;
Gotthardt et al., 2000; Kinoshita et al., 2001; Pietrzik et al., 2004).
These adaptors also bind APP (Fiore et al., 1995; Trommsdorff
et al., 1998). The cytoplasmic adaptor protein, Fe65, links APP
to Lrp1 and enhances amyloidogenic processing of APP (Pietrzik
et al., 2002; Kinoshita et al., 2003; Yoon et al., 2005; Klug et al.,
2011). Dab1 can interfere with this Lrp1/Fe65/APP complex
by competing with Fe65 for Lrp1 binding, thereby reducing
amyloidogenic APP processing (Kwon et al., 2010). Of note,
the ICD of APP along with Fe65 translocates to the nucleus
where it suppresses Lrp1 transcription (Liu et al., 2007). APP
and Lrp1 also share other cytoplasmic interactions, one of which
is with the endosomal sorting nexin 17 (Snx17). Snx17 interacts
with the NPxYmotifs in Lrp1 and APP to regulate their recycling
from early endosomes back to the cell surface (Lee et al., 2008;
Donoso et al., 2009; Farfán et al., 2013).
Despite promoting neuronal Aβ production, Lrp1 participates
in Aβ clearance (reviewed in Kanekiyo and Bu, 2014). Lrp1 binds
Aβ, with higher affinity for Aβ40 than Aβ42 (Shibata et al., 2000;
Storck et al., 2016). Within the brain, Lrp1 endocytoses Aβ
from the extracellular space and directs it to the lysosome for
degradation (Kanekiyo et al., 2013). Lrp1 is also expressed in
astrocytes and microglia where it is involved in Aβ-clearance
(reviewed in Ries and Sastre, 2016). Another major Aβ clearance
mechanism involves the transcytosis of Aβ from the brain to
the circulation via the BBB (Marques et al., 2013). Lrp1 gene
silencing reduced the clearance of intracerebroventricularly-
injected Aβ across the BBB in wildtype mice (Jaeger et al.,
2009). Furthermore, an endothelial (brain and choroid plexus)-
specific Lrp1 knockout revealed that Lrp1 preferentially clears
Aβ40, as these mice accumulated Aβ40 faster and demonstrated
reduced spatial memory (Storck et al., 2016), which is a
common phenotype observed with high levels of Aβ. Moreover,
Lrp1 cleavage by ADAM10 has opposing effects as well;
whereas soluble Lrp1 in the brain inhibits Aβ clearance, in
the periphery it could provide a sink for Aβ monomers.
Inhibition of ADAM10 reduces Lrp1 ectodomain shedding,
thereby promoting Aβ-clearance across the BBB, especially
Aβ40 (Shackleton et al., 2016); however, ADAM10 cleavage of
Lrp1 also leads to the segregation of soluble Lrp1 into the
periphery where it has been described to prevent the reentering of
Aβmonomers into the brain (Sagare et al., 2007). Recently it was
found that another AD risk gene, PICALM, plays a central role in
BBB transcytosis of Aβ, and it has been reported that extracellular
binding of Aβ to Lrp1 induces an intracellular conformational
change allowing for PICALM binding and endocytosis of the
entire complex (Zhao et al., 2015).
Importantly, both the Vldlr- and Lrp1-mediated Aβ clearance
mechanisms via the BBB are differentially slowed down by ApoE-
isoforms: ApoE4>ApoE2 or ApoE3 (Deane et al., 2008). Besides
clearance of Aβ, Lrp1 can compete with APP for BACE1 (von
Einem et al., 2010) and γ-secretase (Lleó et al., 2005) cleavage.
Taken together, it appears that Lrp1 contributes to the Aβ-
homeostasis in two opposing ways: whereas Lrp1 promotes
intraneuronal APP processing towards Aβ (Figure 2), Lrp1 also
provides an important clearance mechanism of Aβ across the
BBB and/or BCSFB (Figure 3).
Lrp1b (LRP-DIT)
Structure and General Physiological
Properties
Lrp1b is very similar to Lrp1 in overall structure and sequence
(∼59% identical).Where Lrp1b differsmost from Lrp1 is an extra
LBR in the ECD and a 33 amino acid insert in the ICD (Liu et al.,
2000). Lrp1b was first associated with tumorigenesis, but is also
highly expressed in the adult brain (Liu et al., 2000; Haas et al.,
2011) and retains APP at the cell surface reducing Aβ production
(Cam et al., 2004).
Genetics
Mutations in Lrp1b are associated with multiple different
types of cancer (Liu et al., 2000; Langbein et al., 2002;
Sonoda et al., 2004), including gliomas (Roversi et al.,
2006). Lrp1b-deficiency leads to embryonal lethality (Dietrich
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FIGURE 2 | Lipoprotein receptors modulate amyloid precursor protein (APP) trafficking and processing in neurons. Neurons are the major source of Aβ
(depicted as green droplets) in the brain. APP (green), all core LDL receptor family members as well as the more distant member SorLA contains at least one
NPxY-motif, which acts as a docking site for PTB-domains of intracellular adaptor/scaffold proteins. Both Fe65 and Dab1 bind APP, as well as a number of LDL
receptor family members (red and orange), via their PTB-domains. The simultaneous binding of these intracellular adaptor/scaffolding proteins to the NPxY motifs of
APP and LDL receptors coordinate their intracellular trafficking, thus regulating APP localization and processing. The adapter/scaffold proteins control the speed of
endocytosis of the receptors in that Fe65 and Dab1 binding to APP masks the endocytosis signal of APP, resulting in the surface retention of APP. This increases the
exposure of APP to α-secretase (α), which cleaves APP inside the Aβ region (dark green) to release a soluble APPα (sAPPα) fragment and ultimately preventing the
production of Aβ. Importantly, Lrp1 and Lrp1b (both orange in the diagram) have drastically different rates of endocytosis, with the internalization rate of
Lrp1 exceeding that of Lrp1b by many-fold. Both bind Fe65, connecting them in a complex APP, and have opposite effects on APP processing. The fast endocytosis
rate of Lrp1 increases the exposure of APP to the endosomal β- (BACE1, β) and γ-secretase (γ), producing Aβ (green tears) and soluble APPβ (sAPPβ) fragment.
Another intraendosomal sorting receptor of the LDL receptor family, SorLA, can bind and reroute receptors from the endosome back to the trans-Golgi network
(TGN), where it is either sequestered, sorted back to the cell surface, or sent to the lysosome for degradation. Apoer2, which also recycles slowly, binds Fe65 via its
NPxY-motif, promoting APP surface stability and decrease amyloidogenic processing. Additionally, simultaneous binding of the secreted, extracellular ligand,
F-spondin, to the ECDs of APP and Apoer2 also promotes APP stability at the surface.
et al., 2010). Like Lrp4 knockins expressing a truncated
ECD (see ‘‘Lrp4’’ Section for details), a similar truncation
of Lrp1b allows animals to survive, be fertile and develop
mostly normal. However, in contrast to Lrp4-ECD (Pohlkamp
et al., 2015) mice, synaptic plasticity in hippocampal field
recording is not affected in Lrp1b-ECD mice (Marschang et al.,
2004).
Biochemistry and Cellular Function
Lrp1b binds to fibrinogen and ApoE carrying proteins (Haas
et al., 2011). In total, Lrp1 and Lrp1b share numerous ligands.
Lrp1b also binds APP at the extracellular KPI-containing
domain (Cam et al., 2004). With an internalization rate of
more than 10 min for Lrp1b, the rate of endocytosis is
much slower than Lrp1, which has a rate of less than 30 s
(Liu et al., 2001). In contrast to overexpression of Lrp1 in
a cell culture system, overexpression of Lrp1b increased APP
surface expression, resulting in enhanced non-amyloidogenic
α-secretase cleavage and reduced Aβ production (Cam et al.,
2004). Based on these in vitro findings, a model for the
Lrp1- vs. Lrp1b-effect on APP processing was proposed by
Wagner and Pietrzik (2012), where fast Lrp1 uptake shifts
APP processing from α-cleavage towards the endosomal toxic
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FIGURE 3 | Lrp2 mediates Aβ-clearance via the blood cerebrospinal
fluid (CSF) barrier (BCSFB). Diagram depicting the Lrp2-mediated
clearance of interstitial Aβ through the cerebral spinal fluid (CSF) into the blood.
In addition to direct astrocytic Lrp2 clearance of Aβ, Lrp2 expressed in the
ependymal cells of the choroid plexus also facilitate Aβ removal. The choroid
(Continued)
FIGURE 3 | Continued
plexus functions to produce and filter CSF. This filtration removes metabolic
waste, excess neurotransmitters and foreign/toxic particles, such as Aβ, which
is mainly produced by neurons (see Figure 2). Apolipoproteins, such as ApoE
and ApoJ/Clusterin (yellow dots), mainly secreted from astrocytes (“Astro”),
bind circulating interstitial Aβ. These Aβ-laden apolipoproteins then bind
lipoprotein receptors (red) and mediate their cellular uptake. ApoJ/Clusterin is
eliminated rapidly across the BCSFB by ependymal Lrp2 (light red), facilitating
the clearance of Aβ via lysosomal degradation in ependymal cells and
subsequent exocytosis into the CSF, where soluble Lrp2 (sLrp2) has been
detected (Spuch et al., 2015). BACE1 is the enzyme that processes Lrp2 and
Lrp1 to release sLrp2 and sLrp1, respectively. BACE1 is also found in the
choroid plexus (Crossgrove et al., 2007; Liu et al., 2013). Other lipoprotein
receptors (dark red, most notably Lrp1) then transport Aβ and the
apolipoproteins across the endothelial cells from the CSF to the blood vessels
of the choroid plexus. sLrp1 can also be detected in plasma, albeit its origin
there is mainly peripheral.
β- and γ-cleavage-pathway, whereas Lrp1b-APP interaction
results in prolonged surface time and increased α-cleavage
of APP (Figure 2). However, it is important to note that
while Lrp1, not Lrp1b, is likely to promote intracellular Aβ-
production, it is conversely important for Aβ-clearance across
the BBB.
Apoer2 (Lrp8) AND Vldlr
Structure, General Physiological
Properties and Genetics
Both Apoer2 and Vldlr are quite similar in size and domain
composition to Ldlr (Figure 1; Kim et al., 1996). The sequence
identity between Vldlr and Apoer2 is approximately 50% (Kim
et al., 1996 and reviewed in Reddy et al., 2011). Apoer2 has
seven ligand-binding repeats, one less than Vldr, and contains
a unique alternatively-spliced proline-rich domain not found
in Vldlr (Kim et al., 1997; Clatworthy et al., 1999; Sun and
Soutar, 1999). In the brain, Apoer2 only contains five ligand-
binding domains due to alternative-splicing of exon 5 (Kim
et al., 1997; Clatworthy et al., 1999; Sun and Soutar, 1999).
The site of least homology between the Apoer2 and Vldlr
is the OLS domain (Kim et al., 1996). As mentioned above,
the OLS domain is alternatively-spliced in both receptors. For
both receptors, splice variants containing the OLS domain are
highly glycosylated, and this glycosylation inhibits proteolytic
processing (Magrané et al., 1999; May et al., 2003; Wasser
et al., 2014). For Vldlr, splice variants lacking this glycosylated
domain undergo rapid proteolytic cleavage (Magrané et al.,
1999). Unlike Vldlr, the OLS domain is required for the initial
extracellular cleavage of Apoer2 (presumably due to loss of
the extracellular cleavage site), so Apoer2 variants lacking the
OLS domain are actually resistant to proteolysis (Wasser et al.,
2014).
Apoer2 and Vldlr are almost exclusively expressed in
the brain where they act as receptors not only for ApoE
but also for the neuromodulator Reelin (D’Arcangelo et al.,
1999; Trommsdorff et al., 1999). Ligand binding increases the
proteolytic processing of both receptors (Hoe and Rebeck,
2005). The proteolytic fragments of Apoer2 can inhibit
further signaling, whereby the soluble ECD fragment acts
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as a dominant negative receptor (Koch et al., 2002) and
the released ICD translocates to the nucleus and represses
Reelin transcription (Balmaceda et al., 2014; Telese et al.,
2015).
The signaling initiated by Reelin binding to Apoer2 and
Vldlr plays essential roles during the development of the
CNS and neuronal function through adulthood (Förster et al.,
2010). During development, Reelin expressed and secreted from
Cajal-Retzius cells modulates the cytoskeleton and mobility of
migrating neurons (Frotscher et al., 2009) and ensures proper
cortical, hippocampal and cerebellar lamination (Trommsdorff
et al., 1999).
Apoer2 and Vldlr double knockout leads to a phenotype
comparable to Reelin or Dab1 deficiency: mice develop strong
ataxia, a smaller cerebellum, and defective lamination of
cerebellum, cortex and hippocampus (Trommsdorff et al., 1999).
Cortical Cajal-Retzius cells die out after birth and the amount
of hippocampal Cajal-Retzius cells dramatically thins out later
during postnatal hippocampal maturation (Chowdhury et al.,
2010). In total, the expression pattern changes so that in
the cortex and hippocampus Reelin is now expressed in a
more distributed fashion, mainly by subtypes of GABAergic
interneurons (Drakew et al., 1998; Pesold et al., 1998; Pohlkamp
et al., 2014). Besides neuronal migration, Reelin-signaling plays
parts in both axo- (Leemhuis et al., 2010) and dendritogenesis
(Assadi et al., 2003; Niu et al., 2004; Jossin and Goffinet, 2007;
Zhang et al., 2007; Kawauchi and Hoshino, 2008; Matsuki et al.,
2008; Chai et al., 2009; Ventruti et al., 2011) as well as synapse
formation and function (Glantz and Lewis, 2000; Sinagra et al.,
2005; Groc et al., 2007; Qiu and Weeber, 2007; Niu et al., 2008;
Campo et al., 2009; Dumanis et al., 2011; Hellwig et al., 2011; Bal
et al., 2013). In the adult brain, Reelin regulates synaptic function,
plasticity and spatial learning and fear memory (Weeber et al.,
2002; Beffert et al., 2005; Herz and Chen, 2006; Wasser et al.,
2014).
Apoer2 and Vldlr bind Reelin and cluster together resulting
in the phosphorylation of Dab1 and Src-kinase-mediated
phosphorylation of NR2 subunits of the NMDA receptor
(Hiesberger et al., 1999; Arnaud et al., 2003; Bock and Herz,
2003; Strasser et al., 2004), which requires a unique 59-amino
acid insert in the Apoer2 cytoplasmic tail through direct
interaction with PSD-95 (Beffert et al., 2005). Reelin-mediated
NMDAR phosphorylation increases Ca2+-influx through
NMDAR, resulting in increased activation of cAMP-response
element binding protein (CREB; Chen et al., 2005) and the
potent enhancement of long-term potentiation (LTP; Weeber
et al., 2002). Hippocampal LTP is modestly reduced or severely
perturbed in mice lacking Vldlr or Apoer2, respectively, and
LTP is not enhanced by acute Reelin treatment in either mutant
(Weeber et al., 2002).
There are several lines of evidence that implicate Reelin
signaling as protective against AD pathogenesis. First, Reelin-
signaling can counteract Aβ-induced synaptic suppression
(Durakoglugil et al., 2009) by enhancing synaptic LTP, an
effect that requires a unique alternatively spliced exon in
the ICD of Apoer2 (Beffert et al., 2005). Interestingly, the
AD-risk factor ApoE4 actually prevents this protective effect
by sequestering the ApoE receptors along with other synaptic
receptors in the endosome (Chen et al., 2010), and postnatal
loss of Reelin exacerbates the cognitive deficits in AD mouse
model (Lane-Donovan et al., 2015). In AD mice, Apoer2 and
its ligand Reelin are localized in fine granular structures and
reactive astrocytes surrounding Aβ plaques (Wirths et al.,
2001; Motoi et al., 2004). Furthermore, both humans with AD
and a transgenic AD mouse model have higher expression of
the Apoer2 splice variant that lacks the alternatively spliced
CTD, which would be predicted to impair the Reelin-mediated
suppression of Aβ-toxicity (Hinrich et al., 2016). Treating these
AD mice with antisense oligonucleotides designed to increase
the inclusion of the alternatively spliced proline-rich domain in
Apoer2 restored the expression of the functional Apoer2 variant
and rescued their AD-related memory deficits (Hinrich et al.,
2016).
Biochemistry and Cellular Function
Both Apoer2 and Vldlr interact with APP-binding proteins
and influence the amyloidogenic processing of APP (reviewed
Hoe and Rebeck, 2008; Marzolo and Bu, 2009; Wagner and
Pietrzik, 2012; Lane-Donovan et al., 2014). Of the two receptors,
Apoer2 interacts with a larger number of APP-binding proteins.
Both APP and Apoer2 bind F-spondin (Ho and Südhof, 2004;
Hoe et al., 2005) and Reelin (Hoe et al., 2009) extracellularly,
as well as the intracellular adaptor proteins X11α/β (Borg et al.,
1996; He et al., 2007), Fe65 (Fiore et al., 1995; Borg et al.,
1996; Hoe et al., 2006a), Snx17 (Lee et al., 2008; Sotelo et al.,
2014), Dab1 (Homayouni et al., 1999; Howell et al., 1999), and
Dab2 (Cuitino et al., 2005; Lee et al., 2008). To date, Vldlr is
known to directly interact with both Reelin and Fe65 (Dumanis
et al., 2012) and immunoprecipitation results supported that
Fe65 increases the interaction between APP and Vldlr in vivo,
suggesting that Vldlr is involved in APP trafficking (Dumanis
et al., 2012).
Ligand binding to Apoer2 induces homotypic clustering
as well as clustering with other receptors, including APP
(Divekar et al., 2014). The clustering of Apoer2 is weaker
with ApoE binding compared to the clustering upon binding
either Reelin or F-spondin (Divekar et al., 2014). ApoE inhibits
γ-secretase cleavage of Apoer2 and APP (Irizarry et al., 2004;
Hoe et al., 2006b), and ApoE3 imparted a greater inhibition
than ApoE4 preventing the release of the Apoer2-ICD and APP
intracellular domain (Hoe et al., 2006b). Interestingly, Apoer2-
deficient mice express more ApoE and have elevated levels of
the aggregation prone form of Aβ (Aβ42; Petit-Turcotte et al.,
2005).
F-spondin is an extracellular ligand for both Apoer2
(Hoe et al., 2005) and APP (Ho and Südhof, 2004). This
secreted extracellular protein, F-spondin, is composed of an
amino-terminal Reelin and F-spondin domains followed by a
thrombospondin domain, which contains six thrombospondin
repeats (TSRs; reviewed in Feinstein and Klar, 2004). The central
portion of the APP-ECD binds within the amino-terminal Reelin
and F-spondin domains, while the LBD of Apoer2 binds the first
four TSRs of F-spondin (Hoe et al., 2005). F-spondin stabilizes
Apoer2 and APP at the cell surface, promoting α-cleavage of
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both proteins and reducing Aβ formation (Hoe et al., 2005).
Of note, other LDL receptor family members-Vldlr, Lrp4 and
Lrp2—also bind the first four TSRs of F-spondin (Zisman et al.,
2007).
Like Lrp1, the NPxY domain of Apoer2 binds the cytosolic
adaptor protein Fe65. While Lrp1 and Fe65 enhance Aβ
production, Fe65 increases the interaction of APP and
Apoer2 and decreases APP processing by stabilizing them at
the cell surface (Hoe et al., 2006a). As Apoer2 and Lrp1 interact
within the same region of Fe65, these two receptors may
compete with each other for Fe65 binding and differentially
influence APP processing (Hoe et al., 2006a). Dab1 also binds
the NPxY motifs of Apoer2 and APP, and Aβ is decreased with
Dab1 overexpression and increased in Dab1-deficient primary
neurons (Hoe et al., 2006c).
Apoer2 directly interacts with APP extracellularly (Fuentealba
et al., 2007). In Lrp1-deficient cells, Apoer2 promotes the
cell surface retention of APP. This stabilization of APP
requires cytoplasmic domain of Apoer2 (Fuentealba et al.,
2007). Co-expression of Apoer2 with APP promotes APP
surface expression and the lipid raft association of APP
dependent on the Apoer2 CTD, but unexpectedly increased
Aβ formation (Fuentealba et al., 2007). In contrast, X11α/β-
binding to Apoer2 mediates ApoE induced endocytosis of
APP and β-secretase resulting in APP processing and Aβ
production (He et al., 2007), and Reelin can interrupt this
interaction between X11α/β and Apoer2 (Minami et al.,
2010), indicating another protective role of Reelin against Aβ
toxicity.
Lrp2 (MEGALIN/gp330)
Structure and General Physiological
Properties
Lrp2 is structurally very similar to Lrp1b and one of the
most studied lipoprotein receptors in conjunction with AD.
Similar to Lrp1, Lrp2 undergoes proteolytic processing to release
the ECD followed by γ-secretase cleavage to release the ICD
(Zou et al., 2004; Biemesderfer, 2006). The Lrp2-ICD contains
sorting signals including three NPxY and a PPPSP motif that
control Lrp2 surface expression specifically at cholesterol- and
glycosphingolipid-rich regions (Marzolo et al., 2003). Besides
binding to APP and ApoE, Lrp2 is also an important receptor
for ApoJ/Clusterin, which is another genetic risk factor for
AD. Lrp2 is expressed on endothelial cells of different organs,
including capillaries in the brain and the ependymal cells of
the choroid plexus, where it controls cholesterol homeostasis
and Aβ-clearance (Willnow et al., 1996; Hammad et al., 1997;
Chun et al., 1999; Bell et al., 2007). Besides its expression in
endothelial and ependymal cells, Lrp2-expression has also been
reported in dying neurons of postmortem brains of AD patients
and cultured astrocytes (LaFerla et al., 1997; Bento-Abreu et al.,
2008).
During neural tube formation and forebrain development
Lrp2 is required for the dorsal to ventral gradient of the
bone morphogenic protein 4 (BMP4) and sonic hedgehog
(Shh). Lrp2 mediates endocytosis of Bmp4 for degradation and
Bmp4 levels are increased in Lrp2-deficient mice (Spoelgen
et al., 2005). Lrp2 is also a required co-receptor for Shh,
ligand-binding induces a positive feedback loop and increased
Shh-expression, thus Lrp2-deficiency leads to the loss of Shh
expression in the ventral neuroepithelium (Christ et al., 2012).
Finally, the loss of the Bmp4-Shh gradient in the neural tube
causes holoprosencephaly, the failure of the brain to develop
into two hemispheres (Spoelgen et al., 2005; Christ et al., 2012).
Moreover, Shh and Lrp2 signaling regulates oligodendrocyte
progenitor migration and proliferation in the optic nerve
(Ortega et al., 2012) and glial cell specification during neural
development (Wicher et al., 2005). The role of Lrp1 and Lrp2 in
regulating neural stem cell and progenitor cell function has been
reviewed in detail elsewhere (Auderset et al., 2016). However
an implication of APP for these mechanisms has not been
described.
Genetics
Lrp2-deficient mice die shortly after birth due to respiratory
insufficiency. Lrp2 function is critical during neural tube
formation, as it acts to organize Shh-mediated forebrain
development during neurulation (Christ et al., 2012). Besides
malfunctioning of endothelial tissues including lung and
kidney, Lrp2-deficiency in neuroepithelium leads to impaired
proliferation and forebrain fusion (Willnow et al., 1996).
Endothelial cell specific Lrp2 deletion leads to impaired
Aβ-clearance, which is described in more detail in the next
section.
Biochemistry and Cellular Function
In the adult brain, Lrp2, facilitated by its ligand ApoJ/Clusterin,
mediates Aβ clearance from the CSF (Hammad et al., 1997;
Bell et al., 2007; Figure 3). As a part of the blood-CSF barrier
(BCSFB), the choroid plexus takes part in the production and
filtration of the CSF, including clearance of Aβ (Figure 2).
Lrp2 is expressed within the choroid plexus, where it is
sorted to the apical surface of ependymal cells within the
lateral ventricles (Zheng et al., 1994; Chun et al., 1999;
Willnow et al., 1999; Carro et al., 2005; Alvira-Botero and
Carro, 2010). Despite a lack of AD pathology, mice lacking
Lrp2 within these ependymal and endothelial cells display
cognition deficits that mimic those in AD mice with elevated
Aβ production (Dietrich et al., 2014). Of note, ApoJ/Clusterin
also binds to Lrp1 (Gil et al., 2013), Vldlr, and Apoer2
(Andersen et al., 2003; Leeb et al., 2014) and alternative
receptors Trem2 (Yeh et al., 2016) and Plexin A4 (Kang et al.,
2016), yet it is not known how ApoJ/Clusterin interactions
with the other LDL receptor family members affects AD
pathology.
Lrp2 expression decreases with age, which goes along with
a reduced clearance rate of Aβ (Carro et al., 2005). In brains
of AD-patients, damaged neurons express more Lrp2 (LaFerla
et al., 1997), and the transcription of Lrp2 mRNA is repressed
by microRNA-146a (Zhang et al., 2016). Genetically, a single
nucleotide polymorphism (SNP) in the Lrp2 promoter that
reduces Lrp2 expression by 20% is considered a risk factor for
Frontiers in Molecular Neuroscience | www.frontiersin.org 9 March 2017 | Volume 10 | Article 54
Pohlkamp et al. APP and LDLR Family Interactions
AD (Vargas et al., 2010; Wang et al., 2011). Additionally, much
like Lrp1, Lrp2 forms a complex with APP and Fe65 to control
neurite branching and APP processing (Alvira-Botero et al.,
2010).
Lrp4 (MEGF7)
Structure and General Physiological
Properties
One of the shorter members of the LDL receptor family, Lrp4,
is critical for survival in that LRP4 knockout mice die after birth
due to defects in the neuromuscular junction (NMJ; Weatherbee
et al., 2006). Lrp4 is also involved in the development of both the
kidneys and limbs as Lrp4 knockout mice display abnormal limb
morphology and renal agenesis (Johnson et al., 2005; Simon-
Chazottes et al., 2006; Karner et al., 2010; Tanahashi et al.,
2016). Additionally, Lrp4 regulates chondrocyte and osteoblast
homeostasis during cartilage and bone growth (respectively)
through binding the ligands Wise/Sostdc1, Dickkopf and
Sclerostin (Choi et al., 2009; Asai et al., 2014). As Lrp4-deficient
mice die due to abnormal NMJ formation, Lrp4 plays a pivotal
role during development at the NMJ where Lrp4 along with
its ligand, the heparan-sulfate proteoglycan (HSPG) Agrin, and
co-receptors muscle-specific tyrosine receptor kinase (MuSK)
and APP act together to orchestrate NMJ formation (Kim
et al., 2008; Zhang et al., 2008; Choi et al., 2013). The
Lrp4 ligand, Agrin, similar to the Apoer2 and Vldlr ligand
Reelin, which also interacts with APP, is a large extracellular
matrix protein with multiple binding domains. On the muscle
fiber membrane, MuSK and Lrp4 form a functional receptor
complex for Agrin. Upon Agrin binding to Lrp4, MuSK is
phosphorylated resulting in Rapsyn-dependent focal clustering
of nicotinic Acetylcholine receptors (nAChR; Shen et al., 2014).
Recent evidence suggests that these components, which are also
expressed in the adult brain, also play a role in synaptic plasticity
and/or AD pathogenesis (Glenner and Wong, 1984; Berzin et al.,
2000; Gomez et al., 2014; Pohlkamp et al., 2015; Sun et al.,
2016).
Genetics
Deficiency in Lrp4, MuSK, Agrin, APP and APLP2, or the
intracellular scaffold Rapsyn lead to neonatal lethality, due to
failure to form NMJs (Gautam et al., 1999; Wang et al., 2005;
Weatherbee et al., 2006). At central synapses, these components
do not appear critical for synapse formation; however, a recent
report demonstrated that Agrin, Lrp4 and MuSK act together on
the astrocyte to control synaptic plasticity (Sun et al., 2016). Lrp4,
like APP, is a substrate for ADAM10 secretase and γ-secretase
and undergoes proteolytic processing by these enzymes to release
soluble ECD and ICD fragments of Lrp4, respectively (Dietrich
et al., 2014). Targeted expression of various Lrp4 truncations in
mice revealed a differential dependence of membrane anchoring
and the presence of the ICD for Lrp4-mediated mechanisms.
Knockins expressing secreted Lrp4-ECD survive, but display
impaired LTP and develop only partially functional NMJs with
abnormal limb development. Alternatively, in mice expressing a
membrane-anchored Lrp4 with deleted ICD limb development
is only mildly affected and LTP is normal (Johnson et al., 2005;
Choi et al., 2013; Pohlkamp et al., 2015).
Studies at the NMJ also revealed important insights how
different members of the APP-family interact (Choi et al., 2013).
In APP/APLP2 mutants, NMJ endplate patterning is severely
impaired, whereas APLP1/APLP2 mutants develop normal
endplate patterning with reduced size and apposition of pre-
and postsynaptic specializations. APLP1 seems to be exclusively
expressed in the neuronal ending of the NMJ whereas APP
and APLP2 are present on both, the muscle and the neuronal
sides (Klevanski et al., 2014). In addition, Fe65/Fe65L1 double
knockout mice show severe motor impairments, NMJ pre-
and postsynaptic appositions, and impaired hippocampal LTP
(Strecker et al., 2016). Fe65 interacts with Apoer2, Vldlr,
Lrp1, Lrp1b, Lrp2, but binding to Lrp4 has so far not been
examined.
Biochemistry and Cell Biology
On the muscle fiber membrane, MuSK and Lrp4 form a
functional receptor complex for Agrin. Upon Agrin binding to
Lrp4, MuSK is phosphorylated resulting in Rapsyn-dependent
focal clustering of nAChR (Shen et al., 2014). APP, and
presumably APLP2, present on the muscle fiber surface and
along with APLP1 on the neuron, also binds to Lrp4 and
Agrin, which is required for the localized clustering of AChR on
the muscle fiber where nerves terminate to allow a functional
NMJ to form (Kim et al., 2008; Choi et al., 2013; Figure 4).
Interestingly, unlike Lrp1 and Lrp1b, in vitro experiments show
that Lrp4 binding to APP does not require the KPI domain in
APP (Choi et al., 2013).
Similar to the lipoprotein receptor ligand Reelin, multiple
functions have been described for Agrin in shaping and
maintaining neuronal activity in the brain. Agrin stimulates
filopodia formation to allow structural plasticity (McCroskery
et al., 2009) and inhibits astrocytic ATP release resulting in
enhanced synaptic glutamate release (Sun et al., 2016). Agrin also
regulates the strength of GABAergic synapses during network
inactivation (Pribiag et al., 2014), reduces Aβ-levels (Rauch
et al., 2011), and contributes to acetylcholine receptor clustering
(Rauch et al., 2011). However, as of now, it is unknown if these
functions require Lrp4-mediated endocytosis and trafficking. For
example, Lrp4 does not require endocytic activity to promote
NMJ formation (Willnow et al., 2012). Agrin binds not only
Lrp4 but also to multiple other receptors and ligands such as
heparin (Wallace, 1990), NCAM (Storms et al., 1996), Integrins
(Martin and Sanes, 1997), α-dystroglycan (Bowe et al., 1994),
Na+/K+ATPase (Hilgenberg et al., 2006) and notably APP (Choi
et al., 2013). Moreover, presynaptic activity dependent release
and postsynaptic activity- dependent activation of the protease
Neurotrypsin regulates Agrin cleavage at α- and β-sites (Reif
et al., 2007; Stephan et al., 2008; Gisler et al., 2013). Specifically
the short C-terminal fragment of Agrin potentially promotes
filopodia outgrowth via α-dystroglycan (Gisler et al., 2013).
Lrp4 also contributes to synaptic plasticity. Mice lacking
Lrp4 or expressing a truncated Lrp4 retaining the ECD (Lrp4-
ECD) in the brain have impaired hippocampal LTP and impaired
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FIGURE 4 | Lrp4 and APP interaction during neuromuscular junction
(NMJ) formation. Illustration depicting the interaction of Lrp4, MuSK, Agrin
and APP/APLP1/APLP2 in the formation of the NMJ. Agrin binds
Lrp4 resulting in phosphorylation (P) of MuSK, which leads to the recruitment
and clustering of acetylcholine receptors (AchRs). The recruitment of AChR to
the NMJ depends on all components of the complex. Knockouts of Lrp4,
MuSK, Agrin, or APP/APLP1/APLP2 result in defective NMJ formation and
perinatal lethality. APP and its family members (APLP1 and APLP2) have
redundant functions, allowing them to compensate if one is knocked out.
APLP1 is expressed on the presynaptic motor neuron, whereas APLP2 and
APP are expressed by both nerve cells and muscle cells. Double knockouts
lacking both APP and APLP1 form functional NMJs and are viable, whereas
APP−/−/APLP2−/− and APLP1−/−/APLP2−/− mice have severely defective
neuromuscular synapses and high postnatal lethality, indicating that APLP2 is
an essential component in NMJ formation, but APP and APLP1 together can
partially compensate in the absence of APLP2. Agrin is expressed in both
neurons and muscle cells, but each express different isoforms. Isoforms
expressed by neurons differ from muscular Agrin by the Z+ splice insert
(yellow star), required for Lrp4 binding (Zong et al., 2012) and NMJ-formation
(Burgess et al., 1999). In addition, besides secreted Agrin, motorneurons
express a TM Agrin, which is not required for NMJ-formation. Extracellular
cleavage of Agrin (α- and β-sites) can be mediated by Neurotrypsin and other
as-yet unidentified proteases (black) expressed at the muscle. While Agrin
cleavage is required for proper NMJ maturation, Neurotrypsin-mediated
cleavage of Agrin is not—despite the fact that Neurotrypsin overexpression
leads to NMJ-failures (Bolliger et al., 2010). The small soluble Z+ containing
C-terminal fragment (after β-cleavage) is sufficient to bind Lrp4 and induce
AChR-clustering, but it is less efficient compared to full length Agrin or Agrin
cleaved at the α-site, only (Zong et al., 2012).
memory (Gomez et al., 2014; Pohlkamp et al., 2015). Importantly,
Sun et al. (2016) showed that the astrocyte-specific knockout of
Lrp4 (using GFAP-Cre) extinguishes all brain Lrp4 expression
and enhances the release of ATP from astrocytes, which
may be causative for the described impairment in LTP. Of
note, GFAP-Cre expression is not restricted to astrocytes and
found in some neuronal populations as well. However, the
authors also demonstrated that Agrin, by binding to Lrp4 and
activating MuSK, controls the ATP release from astrocytes (Sun
et al., 2016). The impaired LTP in Lrp4-ECD mice (Pohlkamp
et al., 2015) suggests that anchoring of Lrp4 to the astrocytic
membrane is required for normal synaptic potentiation. Neurons
exclusively express the TM-Agrin (Neumann et al., 2001)
that contains the alternatively spliced Z+ insert required for
Lrp4 binding. TM-Agrin, by binding to Lrp4 could mediate
a direct interaction of astrocytes and neurons. Furthermore,
activity-driven neurotrypsin cleavage would allow the release
of the Agrin C-terminal Lrp4-binding domain, which then can
diffuse and bind to Lrp4/MuSK complexes on the astrocytic
surface to control ATP release. It needs to be determined if
this pathway requires APP or APLP1/2 in the complex, which
are mainly/exclusively expressed by neurons. The astrocytic
Agrin/Lrp4/MuSK complex together with APP or APLP2 on the
neuronal surface might also be relevant for astrocyte-neuron
interactions.
In the hippocampus, besides neurons, astrocytes express
functional α7-type AchRs (Shen and Yakel, 2012), which
is increased in the brain of AD-patients (Yu et al., 2005).
Importantly Aβ binds to hippocampal α7AchR expressed on
astrocytes, resulting in increased Ca2+ permeability (Pirttimaki
et al., 2013). Activation of α7AchR on astrocytes triggers AMPA
receptor recruitment to glutamatergic synapses, a mechanism
also involved in converting silent synapses to functional ones
(Wang et al., 2013a). At the NMJ Agrin/Lrp4/MuSK/APP
complex formation appears to be required to effectively cluster
AchRs. So far, however, astrocytic α7AchR function has not been
shown to require the formation of an Agrin/Lrp4/MuSK/APP-
complex. However, total AChR clustering in TM-Agrin knockout
mouse brains, expressing only 20% of the Lrp4-binding Z+ Agrin
form, is 4- to 5-fold reduced (Rauch et al., 2011).
Heparan sulfate proteoglycans (HSPG) inhibit
BACE1 mediated APP cleavage (Scholefield et al., 2003).
Thus, Agrin, as the major HSPG accumulating in plaques of
AD-brains (Verbeek et al., 1999) might be a relevant inhibitor
of BACE1. Agrin has also been described to be relevant for the
function of the BBB (Rauch et al., 2011; Steiner et al., 2014).
However, Aβ-clearance via Agrin and Lrp4 in astrocytes is
unlikely, since in the neuron-specific TM-Agrin knockout,
which expresses only 20% of Z+ Lrp4-interacting Agrin, Aβ
clearance is not affected. By contrast, endothelial-specific
knockout of Agrin does reduce Aβ-clearance (Rauch et al.,
2011).
Lrp5/6
Structure and General Physiological
Properties
Lrp5 and Lrp6 share 71% homology and are more distantly
related members of the family. Despite encoding three LBRs
and four EGF-precursor homology domains, compared to the
core members, the domains appear in an inverse order with
the ligand-binding domains adjacent to the TM segment rather
than at the N-terminus. Additionally, their ICDs lack NPxY
motifs. Both receptors have important functions in Wnt/β-
catenin signaling, whereby Wnt and the Frizzled-receptors,
mediate intracellular β-catenin translocation to the nucleus for
transcriptional control of target gene expression (reviewed by
Joiner et al., 2013). Similar to Lrp4, Lrp5 and Lrp6 are involved in
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bone growth (Lara-Castillo and Johnson, 2015), recently Lrp6 has
also been suggested to have a role in AD and APP processing (De
Ferrari et al., 2007).
Genetics
Lrp5 deficiency causes osteoporosis and bone fracture in
mice due to reduced osteoblast proliferation and low
bone mass (Kato et al., 2002), and point mutations have
been found in human patients with altered bone mass.
Lrp5 knockout also leads to defects in cholesterol and glucose
metabolism. Lrp5 and ApoE double knockout mice suffer
from hypercholesterolemia, fat intolerance, and atherosclerosis
(Fujino et al., 2003; Magoori et al., 2003). Mesenchymal
specific Lrp5 and Lrp6 double mutants resembled β-catenin
knockouts, with severe skeletal development defects (Joeng
et al., 2011). Whereas Lrp5 deficiency primarily affects bone
density, Lrp6 deficiency severely affects brain development.
Lrp6 deletion leads to death after birth, similar to Wnt
mutants they have a caudal truncation of the body axis, excess
neural tissue, defects in neural tube closure, loss of paraxial
mesoderm, and mid- and hindbrain defects (Pinson et al.,
2000). A point mutation in an EGF repeat of Lrp6 causes
coronary artery disease with high LDL-levels by affecting Wnt
signaling (Mani et al., 2007). A SNP in a highly conserved
region of LRP6, initially genetically associated with low bone
mass, has now been associated with AD (De Ferrari et al.,
2007).
Biochemistry and Cellular Function
Wnt signaling via Lrp6 has been implicated in neuronal
differentiation (Jeong et al., 2014), commissural axon guidance
(Avilés and Stoeckli, 2016), and adult neurogenesis in the
hippocampal niche (Schafer et al., 2015). Neuronal deletion of
Lrp6 in the forebrain of the mouse leads to defects in synaptic
integrity and memory formation. Furthermore crossing these
mice with APP/PS1 mice led to increased APP processing to Aβ
that in turn inhibited Wnt signaling, resulting in a synergistic
effect on synaptic dysfunction (Liu et al., 2014). Wnt signaling
is also compromised in brains of patients with AD (Liu et al.,
2014).
SorLA (Sorl1/LR11/LRP11)
Structure and General Physiological
Properties
SorLA is a hybrid-type receptor, as the only member of the LDL
receptor family with a Vps10p (yeast vacuolar protein sorting
10 protein) domain and six Fibronectin repeats (Figure 1). SorLA
is predominantly expressed in the brain, especially in neurons
(Jacobsen et al., 1996; Yamazaki et al., 1996), where it acts as
an intracellular sorting receptor transporting cargo, including
APP, between different intracellular compartments in the cell
(Andersen et al., 2005). In addition to familial mutations linked
to AD (Meng et al., 2007), SorLA is reduced in postmortem AD
brains (Scherzer et al., 2004) and in the CSF of AD patients (Ma
et al., 2009).
Genetics
Defective homeostasis of SorLA and its cargo disrupts cellular
function and causes AD, atherosclerosis and obesity (Caglayan
et al., 2014). In mice, SorLA knockout leads to increased Aβ-
levels in the brain, whereas neuronal SorLA overexpression
causes a redistribution of APP to the Golgi, which results in
decreased Aβ production (Andersen et al., 2005).
Biochemistry and Cellular Function
The ICD of SorLA is important for retrograde trafficking from
endosomes to the trans-Golgi network (TGN) by binding to
the retromer complex and anterograde trafficking by interacting
with clathrin-adaptors (Jacobsen et al., 2002; Seaman, 2007;
Fjorback et al., 2012). SorLA binds APP and Aβ to control
their transport from endosomes either to the TGN to prevent
proteolytic APP-breakdown or to lysosomes for Aβ-degradation,
which recently has been reviewed in detail by Schmidt et al.
(2016). The mosaic receptor has different extracellular binding
domains: an N-terminal Vps10p domain followed by an
EGF-precursor homology domain and 11 LBRs. Whereas the
LBRs are important for APP binding and rerouting away from
the proteolytic pathway (Andersen et al., 2005), the Vps10p
domain is responsible for Aβ-binding and the final lysosomal
degradation (Caglayan et al., 2014). The Vps10p domain consists
of a ten-bladed β-propeller fold with a large tunnel that
has a propensity for ligands with a β-sheet formation. An
internal ligand derived from the SorLA propeptide binds in
this tunnel, extends the domain by one β-propeller blade, and
presumably blocks ligand binding (Kitago et al., 2015). The
SorLA propeptide is removed in late Golgi compartments by
furin (Munck Petersen et al., 1999). SorLA and its interaction
with APP have recently been reviewed in detail by Schmidt et al.
(2016).
VERY DISTINCT AND SHORT RECEPTORS
CONTAINING LBRs
Lrp3, Lrp10 (murine Lrp9) and Lrp12 (ST7/Mig13) share high
homology (Battle et al., 2003) and have two ligand-binding
CUB domains, Lrad3 does not have CUB domains (Figure 1).
Even though in the literature all four receptors have been
claimed to be members of the LDL receptor family, the domain
composition puts them into a different class of mosaic proteins.
All four receptors lack EGF-precursor homology domains found
in all other members of the LDL receptor family. All four
receptors have three to five LBRs (Figure 1), but lipoprotein
binding remains to be confirmed, and their CTDs encode
intracellular sorting motifs. Lrad3 and Lrp10 have been shown
to interact with APP, thus we briefly review them in this
section.
Lrp3, discovered in 1998 is expressed in a wide range of
human tissues, including the brain, with the highest expression
in skeletal muscle and ovary. Interestingly, in contrast to other
LDL receptor family members, Lrp3 does not seem to bind to
RAP (Ishii et al., 1998).
Lrp10 (murine Lrp9) is expressed in various tissues,
including the brain. Little is known about its function; only
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one publication describes its involvement in APP processing.
Lrp10 is located in endosomes and in the TGN (Sugiyama et al.,
2000). The cytoplasmic tail interacts with clathrin adaptors that
coordinate shuttling between endosomes and TGN (Boucher
et al., 2008; Doray et al., 2008). Recently, in vitro data showed
that APP interacts with the ECD of Lrp10, and both proteins
colocalize at the TGN. Lrp10 expression in brains of AD patients
is reduced. In cell culture, Lrp10 overexpression induces the
accumulation of APP in the TGN, which results in reduced
APP-surface expression and processing. Conversely, knockdown
of Lrp10 led to increased processing of APP to Aβ (Brodeur et al.,
2012).
Lrp12 (ST7/MG13) has been annotated as a member of the
LDL receptor family in 2003 (Battle et al., 2003). The Lrp12s
ICD contains several motifs implicated in endocytosis and
signal transduction. Lrp12 is important during CNS development
where it controls the formation of the cortical plate, neuronal
polarity, and migration (Schneider et al., 2011; Wang et al.,
2013b). It is also involved in tumorigenesis including epilepsy-
associated gangliogliomas (Garnis et al., 2004; Robens et al.,
2016). Silencing of Lrp12 in primary neurons leads to increased
dendritic branching, silencing of Lrp12 in the mouse brain
during brain development leads to cortical dyslamination and
seizure sensitization (Grote et al., 2016). As of today, no role in
AD has been described. However, Lrp12 is expressed in neurons
and astrocytes of the adult brain (Grote et al., 2016).
Lrad3 has the shortest ECD of all receptors (Figure 1),
with only three LBRs. Lrad3 is found in the brain and
is expressed in microvascular endothelial cells and neurons
(Otsuki et al., 2005; Ranganathan et al., 2011). In cell culture,
the results of Lrad3 overexpression were similar to those of
Lrp1: Lrad3 promoted the pathogenic proteolytic pathway of
APP, shifting it away from the α-secretase pathway towards
the endosome, resulting in enhanced Aβ production. While
Lrad3 does not interact with Aβ, the receptor does interact
with the central APP fragment (C99) that contains the ICD, the
TM-domain, and a short ECD (Ranganathan et al., 2011). The
Lrad3-ICD contains two PPxY motifs to which WW-domain
containing proteins, e.g., ubiquitin ligases, bind (Ingham et al.,
2004). More recently, it was found that Lrad3 is a component of
the ubiquitin proteasome system by activating the E3 ubiquitin
ligases Itch and Nedd4 (Noyes et al., 2016). However, a direct
role of Lrad3 regulation of ubiquitination to APP processing has
not been established.
LIPOPROTEIN RECEPTORS AND APP
BEYOND ALZHEIMER’s
The function of APP and Aβ beyond AD is not well
understood and understudied, especially in conjunction with
lipoprotein receptors. Different chapters of this series discuss
the physiological role of APP and its cleavage products from
various physiological perspectives. APP and its trafficking and
processing plays a role in neurite outgrowth and synaptogenesis,
APP-deficiency decreases dendritic spine numbers and impairs
LTP, which can be rescued by sAPPα but not sAPPβ (Tyan et al.,
2012). APP function is largely occluded in single APP mutants,
since its paralogs APLP1 and APLP2 can partially compensate
for APP-loss. Characterization of combined knockouts of APP
and its close relatives APLP1 and APLP2 provides additional
insights into the trophic functions of APP: whereas single
knockouts and APLP1/APP double knockouts are viable and
fertile, combined APLP2/APP or APLP1/APLP2 knockouts
display reduced viability (Heber et al., 2000). This suggests
that APLP2 carries the most essential physiological functions
that can be partially compensated by redundancy in the other
family members. APP and APLP2 are expressed ubiquitously,
while APLP1 expression is restricted to the nervous system
(Lorent et al., 1995). Lrp4, MuSK, Agrin and APP/APLP2 are
essential components of a functional complex that recruits and
clusters acetylcholine receptors at the NMJ (reviewed in the
‘‘Lrp4’’ Section). Additionally, Lrp4 does not require the KPI
domain to bind APP (Choi et al., 2013).
APP trafficking and processing is controlled by a large
variety of proteins, but little is known about their physiological
relevance. APP interacts with numerous type-I TM receptors,
many of which are lipoprotein receptors, and several other
ligands, adaptor and scaffolding proteins, which together provide
a protein-protein network involved in signaling, processing of
various receptors, partially through endocytic pathways.
CONCLUDING REMARKS
APP processing to Aβ and in particular the accumulation of the
amyloidogenic Aβ42 product, either from increased production
or impaired clearance, are initiating events in AD, and ApoE
genotype is themost important late onset risk factor for AD. Both
APP and ApoE interact with LDL receptor family members to
regulate APP trafficking, processing and elimination. Therefore,
it is all but certain, that LDL receptor family members play a
pivotal role in the pathogenesis of AD.
As a result of the work reviewed in this article, we have learned
much about the potential molecular mechanisms that these
lipoprotein receptors play in AD pathogenesis, yet the relative
importance of each individual event is still unclear. Continuing
work on the biology of LDL receptor related genes and their
ligands on the physiology of the APP processingmachinery holds
great promise not only to greater understanding of the disease
process but also for the identification of novel and effective
therapeutic approaches.
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